"Drug Inverse Agonism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Phenomena and pharmaceutics of compounds that bind to the same receptor binding-site as an agonist (DRUG AGONISM) for that receptor but exerts the opposite pharmacological effect.
| Descriptor ID |
D054314
|
| MeSH Number(s) |
G07.690.773.968.393
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Inverse Agonism".
Below are MeSH descriptors whose meaning is more specific than "Drug Inverse Agonism".
This graph shows the total number of publications written about "Drug Inverse Agonism" by people in this website by year, and whether "Drug Inverse Agonism" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Inverse Agonism" by people in Profiles.
-
Zanotti-Fregonara P, Hirvonen J, Lyoo CH, Zoghbi SS, Rallis-Frutos D, Huestis MA, Morse C, Pike VW, Innis RB. Population-based input function modeling for [(18)F]FMPEP-d 2, an inverse agonist radioligand for cannabinoid CB1 receptors: validation in clinical studies. PLoS One. 2013; 8(4):e60231.
-
Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2013 Feb; 33(1):118-20.
-
Ward SJ, Raffa RB. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring). 2011 Jul; 19(7):1325-34.